TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05015491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight Program
Description: The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Users are encouraged to log their weight (Weight Logging) at least 1x/week and log their food and beverages (Food Logging) daily. Exercise logging (steps via automatic collection or manually added) is done daily. The Noom Food color grading system is founded on calorie-density (Volumetrics diet, Barbara Rolls) and is a simple and effective method for creating long lasting changes in diet and food choice. Coaches are contacted via In-app messaging or phone communication.
Study: NCT05225181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perform physical exercise
Description: one 60-min session of physical training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perform physical exercise
Description: one 60-min session of physical training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: one 60-min session of cognitive training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: one 60-min session of cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: perform body stretching(15min) and health education courses(90min)
Study: NCT04995640

Intervention type: PROCEDURE
Intervention: open cardiovascular repair or endovascular treatment (TEVAR)
Description: Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
Study: NCT06382857

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MDF
Description: MDF will be provided to children on a weekly basis for children with SAM and bi-weekly basis for children with MAM at the health center until programmatic recovery but not thereafter.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUTF
Description: RUTF will be provided to all children on a weekly basis at the health center until programmatic recovery but not thereafter

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUSF
Description: RUSF will be provided on a biweekly basis at the health center until programmatic recovery but not thereafter
Study: NCT06034821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subanesthetic dose intravenous ketamine (KET)
Description: This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
Study: NCT03945305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
Study: NCT06197698

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F18-FDG, Tc-99m TRODAT-1
Description: In this project, 18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients, and the nigrostriatal dopamine system is assessed by Tc-99m TRODAT-1 SPECT.
Study: NCT05698693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep intervention
Description: The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact Control
Description: This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
Study: NCT05252585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~* Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~* Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)
Study: NCT04359888

Intervention type: OTHER
Intervention: Multi-Modality Balance Intervention
Description: Three one-hour training sessions 2-3x per week for six weeks in Multi-Modality Balance Intervention (MMBI). (See Study Design)

Intervention type: OTHER
Intervention: Balanced Reach Training (BRT)
Description: One-hour training sessions 2-3x per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
Study: NCT05923541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-02 cell infusion
Description: Universal CAR-T cells targeting CD7
Study: NCT05428267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: Completion of questionnaires (IIEF5/FSFI, SF 36, Fatigue Scale Score, Self Esteem Inventory, Hospital Anxiety and Depression Scale) during the pre-transplant consultation, then during a consultation 6 months after transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood collection
Description: Collection of 2 tubes of 5mL of blood during a scheduled blood draw in the patient's care pathway. This sample will also be taken after the transplant (6 months later)
Study: NCT06649175

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Close kinetic chain (CKC) exercises :~1. Supine wall push exercise: Start position: supine with the both leg against wall, other limb straight. Exercise action: push against wall for thirty seconds.~2. Wall push against Swiss ball exercise: Start position: Supine with a Swiss ball between patient's legs and the wall. Exercise action: push against the wall for thirty seconds.~3. Supine half bridging exercise: Start position: Lying on back, knees bent Exercise action: keeping spine neutral and hinging up from the hips, move into a bridge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Control Group (A): will receive the traditional physical therapy (PT) , the traditional physical therapy program will include the following:~* Stretching exercise for shortening muscle of lower limbs (LL) mainly (hip flexors, adductors, knee flexors and ankle planter flexors).~* Balance training from standing while giving perturbations.~* Balance board training.~* Step ups: repeated stepping anteriorly and laterally onto a step with both legs alternatively, progressing to higher step and decreasing upper extremity support.~* Forward and backward walking (with or without handheld mobility devices).~* Side walking (with or without handheld mobility devices).~* Walking in astride line (with or without handheld mobility devices).
Study: NCT06649357

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MoLEP
Description: Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiTURP
Description: Patients with an indication for surgery for BPH viaEEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
Study: NCT03945305

Intervention type: OTHER
Group type: OTHER
Intervention: Previous antihypertensive treatment
Description: Patients are only treated with previous antihypertensive treatment.
Study: NCT05354037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel matrix derivative application for treatment of intrabony defects
Description: EMD application will be associated to M-MIST approach in control group and flapless approach in test group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative application for treatment of intrabony defects
Description: EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
Study: NCT04842331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301 (a nitric oxide generating solution)
Description: Administration is simple and convenient; each dose of RESP301 is administered 3 times daily (at least 4 hours apart) via inhalation using a portable handheld vibrating mesh nebuliser for approximately 8-10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Participants will receive institutional SOC for the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Participants will receive institutional SOC for the treatment.
Study: NCT05580874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: The babies in the massage group were given a massage once a day.

Intervention type: OTHER
Group type: OTHER
Intervention: Swaddling
Description: Control group
Study: NCT06136676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 1 - Heart-Centred Spiritual Meditation: Christian contemplation
Description: Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks focused on Christian contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Christian tradition and prayer recitation with breathing to focus their attention on and connection to God.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 1 - Heart-Centred Spiritual Meditation: Islamic contemplation
Description: Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 weeks, focused on Islamic contemplation delivered through a mobile app. The intervention will consist of a core contemplative practice focused on heart visualisation based on Islamic tradition and prayer recitation with breathing to focus attention on and connection to God.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 - Action Control: Mindfulness Meditation
Description: Participants assigned to this condition will receive daily audio instructions of approximately 20 minutes daily over the course of 8 week, focused on mindfulness meditation delivered through a mobile app. The intervention will consist of the mindfulness-based stress reduction program which emphasizes focused attention on breathing and sensations as well as the practice of non-judgemental acceptance of the present experience.
Study: NCT05032183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05709418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensiv support for first graders in Norway
Description: Intervention targeting early numeracy skills that are known to be important for mathematical development, focusing on counting skills, counting strategies, number knowledge, word problem solving and basic understanding of addition and subtraction
Study: NCT05263908

Intervention type: DRUG
Intervention: nirmatrelvir / ritonavir
Description: The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.
Study: NCT04777942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neo-TACE-HAIC+Surgery
Description: transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone
Description: hepatic resection remove the liver tumors
Study: NCT05506618

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab
Description: Collection of one more nasal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab
Description: Collection of one more nasal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab
Description: Collection of one more nasal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Collection of one more nasopharyngeal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Collection of one more nasopharyngeal swabs

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Collection of one more nasopharyngeal swabs
Study: NCT05032183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT
Study: NCT06035692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: According to the results of the preliminary experiment, the BPB group was given ultrasound-guided BPB with 0.15% ropivacaine 20ml.The ropivacaine concentration was the 90% minimum effective concentration(MEC90) for preventing vasospasm during operation.
Study: NCT06300190

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biceps tenodesis alone
Description: Biceps tenodesis in superior labrum anteroposterior lesion type IV

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biceps tenodesis and labrum repair
Description: Biceps tenodesis and labrum repair by anchors in superior labrum anteroposterior lesion type IV
Study: NCT04818125

Intervention type: OTHER
Group type: OTHER
Intervention: Patients with breast cancer (stage I, II III or IV)
Description: Blood samples will be collected at different times:~* at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);~* at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)~For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study.
Study: NCT04009759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Solution
Description: Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
Study: NCT05032183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC
Study: NCT06271148

Intervention type: OTHER
Intervention: Interview
Description: We made multiple interviews with randomly selected surgical candidates
Study: NCT05032183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Give IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT04560803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CelluTomeTM Epidermal Harvesting System
Description: Autologous epidermal grafts that will be placed at the treatment site
Study: NCT05173922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety in Dementia
Description: Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety in Dementia
Description: Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
Study: NCT04715880

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block/Intercostal Block (PVB/ICB) group
Description: A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block (PVB) group
Description: A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
Study: NCT05676697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
Study: NCT05204849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IRRAflow
Description: Ventriculostomy using IRRAflow with active irrigation and aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ventriculostomy
Description: Standard passive external ventricular drainage
Study: NCT06716970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR12000 150mg
Description: QR12000 150mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR12000 150mg placebo
Description: Matching placebo of QR12000 150mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QR12000 150mg placebo
Description: Matching placebo of QR12000 150mg QD
Study: NCT06496984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Diet changes with different dietary therapies, such as oral nutritional supports (ONS), extra nutritional cares, diet changes without supplements and artificial nutrition.
Study: NCT06131411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health promotion
Description: Co-created culture-tailored intervention of health promotion aimed to increase healthy diet, physical activity and compliance with treatment protocols for diabetes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Health promotion activities routinely performed by Diabetes clinics at the recruiting centres.
Study: NCT06034366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: 0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
Study: NCT06019533

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LVDS
Description: Levonorgestrel Vaginal Delivery System